Search
Recommendation for hematologists in COVID-19 crisis
Recommendations for hematologists in COVID-19 crisis
COVID-19, caused by SARS-CoV-2, is expected to be a devastating infection in patients with active cancer. It should be taken seriously and managed rigorously without jeopardizing the curative chance of individual cancer patients.
EHA statement on coronavirus (COVID-19)
The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).
Read moreThe HARMONY project: learning to work in BIG (DATA) teams
The HARMONY project: learning to work in BIG (DATA) teams
By Anna Kabanova PhD, YoungEHA committee member
On 26 and 27 September 2019 several YoungEHA members, including myself, had the chance to participate in the 4th General Assembly of the HARMONY Alliance…
Meet Michaela Gruber, our December volunteer of the month
Can you tell us what you do for EHA and when you started?
Over six years ago, I was one of the initiators of what is now the “YoungEHA” and the “Young-EHA Committee”.
Meet Michaela Gruber, our December volunteer of the month
Can you tell us what you do for EHA and when you started?
Over six years ago, I was one of the initiators of what is now the “YoungEHA” and the “Young-EHA Committee”.
Revising the ICH Guidelines on Clinical Trials
The EHA delegation to the ICH meeting: from left to right, Professors Christian Gisselbrecht, Steven Le Gouill and Martin Dreyling. Clinical trials and drug development have become more complex over the years.
Read moreThe past and future of the EU Blood, Tissues and Cells legislation
Photo credit: Ineke Oostveen
Blood, tissues and cells (BTC) are used in medicine and in hematology on a daily basis.
EHA at ICH meeting: Excessive bureaucracy harms patient safety and innovation
To solicit input from a wide range of non-ICH members about the revision of ICH E8(R1), ICH held a Public Meeting on ICH E8(R1) “General Considerations for Clinical Studies” (Silver Spring, USA, October 31, 2019).
Read moreWithout access to treatment, can we truly innovate in rare diseases?
Interview with Giampaolo Merlini
There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.
“Nothing about us without us”: how patient advocacy is changing the game
Nuno Borges MBBS MRes, on behalf of YoungEHA
When it comes to advancing medical care, there is no denying that patients are at the core of everything we do.